View Older Stories View More Recent Stories
-
Valeant selects trio to fill in for ailing CEO; shares dive
-
Valeant says CEO J. Michael Pearson hospitalized with severe pneumonia
-
Valeant says can contain hit to dermatology, projects 2016 growth
-
Exclusive: Valeant considers selling contact lens maker Paragon - sources
-
Valeant Pharma (VRX) Issues Update in Response to Misleading Reports
-
Ackman boosts stake in drugmaker Valeant
-
U.S. investigative panel to look into drug pricing next year
-
VRX INVESTORS NOTICE: Lieff Cabraser Reminds Investors of Deadline in Securities Class Action Against Valeant Pharmaceuticals International, Inc.
-
PDL BioPharma (PDLI) Issues Clarification on Glumetza Royalty Rights (VRX)
-
Wall St slips after mixed earnings as jobs report looms
-
VRX INVESTORS ALERT: Lieff Cabraser Reminds Investors of Deadline in Securities Class Action Against Valeant Pharmaceuticals International, Inc.
-
Valeant Pharma (VRX), Retrophin (RTRX) Continue Slump Amid Senate Committee Price Hike Investigation
-
Goldman Sachs says Valeant has long road ahead, cuts rating
-
Valeant's ambitious plan for its contact lens business
-
VRX INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Valeant Pharmaceuticals International, Inc.
-
Top U.S. drugmakers ride new products to strong results
-
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Valeant Pharmaceuticals International, Inc. Investors
-
Drugmaker Valeant raises detailed defense but doubts remain
-
Valeant stock rebounds, but allegations shrink CEO's fortune
-
Valeant's looming M&A hiatus deals blow to investment banks
-
Valeant shares continue slide since Citron report
-
Valeant vows to refute 'phantom sales' allegations
-
Specialty pharmacies in spotlight as Valeant ties questioned
-
Mizuho Weighs in on Panic in Specialty Pharmaceuticals Sector (VRX) (AGN) (ENDP) (SCMP) (JAZZ) (MNK)
-
Moody's Lowers Outlook on Valeant Pharma (VRX) to Stable; Ratings Affirmed
-
Valeant CEO sees new drug pricing environment ahead
-
Valeant's (VRX) Buy Rating Reiterated at BofA/Merrill Lynch
-
Valeant subpoenaed by U.S. prosecutors; shares drop
-
Valeant Pharma (VRX) Refutes Short-Seller Allegations
-
Top 10 News for 09/28 - 10/2: Nonfarm Numbers Lag in Sept.; Splitsville for Alcoa; Initial Sales of Apple's Latest iPhone Set Record
-
Valeant Pharmaceuticals (VRX) Subpoena 'Far from Certain', UBS Says; Sees Bounce Back in Stock
-
Fear and Uncertainty Creates Buying Opportunity in Valeant (VRX) - BMO Capital
-
Market Wrap: Stocks Slip as China Industrial Profits Slide; Apple Hits Record iPhone Sales; Valeant Subpoenaed Over Drug Pricing
-
Democrats take aim at drug prices, prompting sharp drops in biotech stocks
-
Citron Research Negative on Valeant Pharma (VRX); Sees Stock Dropping to $130
-
House Oversight Committee Democrats Request Subpoena of Valeant Pharma (VRX)
-
Valeant Pharma (VRX) Updates on Recent Stock Price Action; Refutes Media Speculation
-
Wall Street drops as anxious investors eye China
-
Hillary Clinton All Bark, No Bite with Biotech Tweet
-
Hillary Clinton Tweet Doesn't Change Bullish View on Valeant Pharmaceuticals (VRX), BMO Capital Says
-
Market Wrap: Existing Sales Outpace in July; Valeant Moves on Sprout Pharma; Trian Welcomed to Sysco's Board
-
Moody's Lifts Outlook on Valeant Pharma (VRX) to Positive
-
Moody's Revises Outlook on Valeant Pharma (VRX) to Stable; Affirms Ratings
-
Allergan (AGN) Slams Valeant's (VRX) Q2 Report
-
Allergan (AGN) Rejects Unsolicited Exchange Offer from Valeant (VRX)
-
Allergan (AGN) Rejects Revised Offer from Pershing Square, Valeant (VRX)
-
Pre-Open Movers 4/22: (RVNC) (AGN) (NFLX) Higher; (MDSO) (BEBE) (RMBS) Lower (more...)
-
After-Hours Movers 4/21: (AGN) (VRX) (NFLX) Higher; (RMBS) (CDNS) (ALSN) Lower (more...)

